Particle.news
Medicaid Pharmaceuticals Medical Education Drug Pricing Pharmaceutical Pricing Insurance Public Health Initiatives Nursing Care Insurance Pharmaceutical Industry Universal Health Coverage Veterans Affairs Affordable Care Act NHS Research Funding Health Financing Medical Access Mental Health Public Health Language Rights Hospital Administration Medicare Rural Health Access to Care Medical Regulations Ayushman Bharat Scheme Regulations Commission Structure Abortion Access Prescription Drug Pricing Healthcare Initiatives Budget Cuts Public-Private Partnerships Regional Health Services Sick Leave Management Administrative Reforms Nursing Care Social Insurance Labor Relations Long-Term Care Patient Rights Pharmaceutical Benefits Scheme Biosimilar Development Healthcare Financing Rural Healthcare Medication Distribution Ambulance Services Healthcare Administration Drug Advertising State Intervention Pharmaceutical Advertising Public Trust Vaccine Access Cancer Care Care Allowances Pharmaceutical Policy Long-term Care Funding and Resources Employee Benefits Healthcare Reform Vaccination Cancer Screening Health Systems Benefits Health Insurance Funding Medical Cannabis Fertility Care Reproductive Health Fertility Treatments Patient Support Medical Economics Pediatric Care Medical Education Policy Healthcare Staffing Pharmacy Regulations Physiotherapy Medical Debt International Healthcare Civil Rights Language Access Social Welfare Consumer Protection Patient Data Management Medical Colleges Medicare and Medicaid Gender Dysphoria Gender Identity Emergency Services Nursing Standards Medical Workforce Home Care Programs Medical Infrastructure CMS Regulations Medicine Availability Department of Health Cashless Treatment Hospital Oversight
The effort targets fast-rising Medicaid prescription costs that reached more than $100 billion in 2024, with net spending about $60 billion after rebates.
